Ratings Thermo Fisher Scientific Berne S.E.

Equities

TFS

US8835561023

Delayed Berne S.E. Other stock markets 09:30:02 02/04/2024 pm IST			5-day change	1st Jan Change
514.5 ^CHF	-0.35%		-0.35%	+19.58%

24/05	Declaration of Voting Results by Thermo Fisher Scientific Inc	CI
22/05	Thermo Fisher Scientific Keeps Quarterly Dividend of $0.39 a Share, Payable July 15 to Shareholders of Record on June 14	MT

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company is in debt and has limited leeway for investment
With an expected P/E ratio at 35.95 and 30.84 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC	+19.58%	219B	-
DANAHER CORPORATION	+11.83%	192B	B-
INTUITIVE SURGICAL, INC.	+18.87%	142B	B-
BOSTON SCIENTIFIC CORPORATION	+30.03%	111B	A-
SIEMENS HEALTHINEERS AG	+1.44%	65.32B	A-
EDWARDS LIFESCIENCES CORPORATION	+14.15%	52.45B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	49.8B	B+
AGILENT TECHNOLOGIES, INC.	+6.60%	43.43B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.85%	35.95B	-
RESMED, INC.	+20.43%	30.43B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes